


48. Neruda P., General introduction; potential strategies to treat liver fibrosis. 2009. 6-33.

49. Friedman SL., Bansal MB., Reversal of hepatic fibrosis – Fact or fantasi ?. Hepatology 2006; 43; S82-S88.

50. Sebastian G, Alberti A. Noninvasiv fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol 2006;12; 3682-3694.


53. Wong et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease (abstract). Hepatology 2010;51:454-462

54. Rust FM. et al., Elastrography for noninvasive assessment of liver fibrosis in chronic viral hepatitis. AJR. 2007; 188; 758 – 64.


60. William AL, Hoofnagle J H, Ratio of serum aspartate to alanine transferase in chronic hepatitis, Relationship to cirrhosis, Gastroenterology 1988; 95; 734 – 9.


64. Sastroasmoro S., Dasar dasar metodologi penelitian klinis, Perkiraan besar sampel, Sagung seto, edisi 3, 2008; 302 – 331


73. De Ledinghen V. Liver stiffness measurement in children using fibroScan: feasibility study and comparison with fibrotest, aspartate transaminase to platelet ratio index, and liver biopsy. Journal of pediatric gastroenterology and nutrition. 2007.45; 443 – 450.


76. Mahtab M et al. Non-Invasive Markers Of Hepatic Fibrosis In Chronic Hepatitis B: a Review; 2008, 61 – 70

77. Friedrich-Rust et al; Real-time Elastography for Non-invasive Assessment of Liver Fibrosis in Chronic Viral Hepatitis. AJR 2007, 758-764